What Tricyclic Antidepressant (TCA) is recommended for the treatment of Obsessive-Compulsive Disorder (OCD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clomipramine for Obsessive-Compulsive Disorder (OCD)

Clomipramine is the only tricyclic antidepressant (TCA) recommended for OCD treatment, typically used as a second-line option after SSRIs due to its less favorable side effect profile despite comparable efficacy. 1, 2

Efficacy and Position in Treatment Algorithm

  • Clomipramine was the first agent to demonstrate efficacy in OCD and has FDA approval specifically for treating obsessions and compulsions in OCD patients 3
  • While some meta-analyses have suggested clomipramine may be more efficacious than SSRIs, head-to-head trials directly comparing clomipramine with SSRIs indicate equivalent efficacy 1, 2
  • SSRIs are preferred as first-line agents due to their superior safety and tolerability profile compared to clomipramine 1, 2
  • According to treatment algorithms, clomipramine should be considered after inadequate response to SSRIs 1

Dosing and Administration

  • Higher doses of clomipramine are associated with greater treatment efficacy for OCD compared to doses used for other conditions 2
  • The maximum dose is 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for children and adolescents 3
  • An 8-12 week trial is considered optimal to determine efficacy 1
  • Patients on clomipramine experienced a mean reduction of approximately 10 points on the Yale-Brown Obsessive Compulsive Scale (YBOCS), representing an average improvement of 35-42% among adults and 37% among children and adolescents 3

Safety Considerations and Monitoring

  • Clomipramine has significant anticholinergic effects and a less favorable side effect profile compared to SSRIs 2, 4
  • Common adverse effects include dry mouth, visual disturbances, constipation, sexual dysfunction, somnolence, tremors, and dizziness 5
  • Clomipramine exhibits potential for cardiotoxicity by impairing conduction and/or causing orthostatic hypotension 5
  • It can lower seizure threshold with a reported 0.4% incidence of seizures 4
  • Careful medical supervision and adherence to prescribing guidelines are essential to reduce medication risk factors 5

Use in Treatment-Resistant OCD

  • For patients with inadequate response to SSRIs, clomipramine may be used as an augmentation strategy 2
  • In a double-blind, randomized controlled trial comparing pharmacological strategies in SSRI-resistant OCD, fluoxetine plus clomipramine significantly reduced OCD severity 1
  • Caution is needed when combining clomipramine with SSRIs due to increased risk of severe and potentially life-threatening events such as seizures, heart arrhythmia, and serotonergic syndrome 1, 2
  • Low-dose combinations (clomipramine 25-50 mg with fluoxetine 20-40 mg) may potentiate therapeutic effects while minimizing adverse effects in treatment-resistant cases 6

Long-term Treatment Considerations

  • Recommended maintenance duration after achieving remission is a minimum of 12-24 months 1, 2
  • Longer treatment might be necessary due to high risk of relapse after discontinuing medication 1
  • The effectiveness of clomipramine for long-term use (more than 10 weeks) has not been systematically evaluated in placebo-controlled trials 3
  • Periodic reevaluation of the long-term usefulness of clomipramine for individual patients is recommended 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clomipramine Efficacy and Treatment Considerations for OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clomipramine for obsessive-compulsive disorder.

American family physician, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.